Latest News - LabCorp
Top Corporates Hub
LabCorp
Labcorp Alzheimer’s Blood Test And Neurology Hire Spark Valuation Debate
19.02.2026 05:12
Labcorp Holdings (NYSE:LH) launched the first FDA cleared blood test to aid in the initial assessment of Alzheimer’s disease, the Elecsys pTau-181 test, with nationwide availability. The company also appointed Dr. John H. Sampson, a leading neurologist and researcher, to its Board of Directors. Labcorp, a large player in diagnostics and central laboratory services, is moving deeper into neurology focused testing with this Alzheimer’s blood test. The test offers a less invasive option...
Baird Maintains Outperform on Labcorp Hldgs, Raises Price Target to $326
18.02.2026 09:05
Baird analyst Eric Coldwell maintains Labcorp Hldgs (NYSE:LH) with a Outperform and raises the price target from $313 to $326.
LH Q4 Deep Dive: Specialty Testing and Hospital Partnerships Offset Volume Challenges
18.02.2026 05:32
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 5.6% year on year to $3.52 billion. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $14.7 billion at the midpoint. Its non-GAAP profit of $4.07 per share was 3.2% above analysts’ consensus estimates.
Labcorp Holdings Inc. Q4 2025 Earnings Call Summary
18.02.2026 01:06
Moby summary of Labcorp Holdings Inc.'s Q4 2025 earnings call
Labcorp Announces 2025 Fourth Quarter and Full Year Results
17.02.2026 11:50
Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the fourth quarter and full year ended December 31, 2025, and provided 2026 guidance.
Labcorp (LH) To Report Earnings Tomorrow: Here Is What To Expect
16.02.2026 03:07
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) will be announcing earnings results this Tuesday before market hours. Here’s what investors should know.
Labcorp's Q4 Earnings Preview: What's in Store for the Stock?
10.02.2026 13:57
LH heads into its Q4 earnings report with rising revenue and EPS expectations, driven by Diagnostics momentum, acquisitions and expanding test demand.
Assessing Labcorp Holdings (LH) Valuation After Guidance Cut And Restructuring Response
05.02.2026 01:09
Event driven focus on Labcorp Holdings (LH) Recent fund commentary flagged Labcorp Holdings (LH) as a performance detractor after reduced guidance tied to delayed acquisitions, a softer development pipeline, and a related business restructuring drew a measured reaction from investors. See our latest analysis for Labcorp Holdings. Those concerns around delayed acquisitions, a softer development pipeline, and restructuring came against a backdrop where Labcorp’s share price has a year to date...
MASHNET Announces Founding of MASLD Diagnostic Coalition
03.02.2026 14:38
MASHNET, a liver Network of Excellence powered by Petauri Kinect, announced today the formation of the MASLD Diagnostic Coalition, a multistakeholder collaboration united by a shared goal to advance access and awareness of non-invasive diagnostics for metabolic dysfunction-associated steatotic liver disease (MASLD).
Investor Concerns Impacted Labcorp (LH) in Q4
03.02.2026 13:10
Diamond Hill Capital, an investment management company, released its “Large Cap Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets continued their upward momentum in Q4, with the Russell 1000 Value Index increasing 3.8%. The information technology (+11%) and communication services (+9%) sectors are leading the rally, driven by […]
2 Unprofitable Stocks with Promising Prospects and 1 We Turn Down
19.01.2026 04:34
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Is Labcorp (LH) Quietly Reframing Its Oncology Innovation Story With Dividends And MRD Expansion?
16.01.2026 05:10
Earlier this week, Labcorp Holdings Inc. declared a quarterly cash dividend of US$0.72 per share, payable on March 12, 2026 to shareholders of record as of February 27, 2026. In parallel, Labcorp expanded its Plasma Detect molecular residual disease portfolio with highly sensitive ctDNA tests for breast, lung and colon cancers, reinforcing its role in precision oncology diagnostics and personalized post-treatment monitoring. We’ll now examine how Labcorp’s expanded MRD testing portfolio...
Labcorp Declares Quarterly Dividend
14.01.2026 11:50
Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2026, to stockholders of record as of the close of business on February 27, 2026.
3 Value Stocks Walking a Fine Line
14.01.2026 04:33
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk
13.01.2026 12:00
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the continued expansion of its molecular residual disease (MRD)i portfolio designed to help clinicians detect cancer recurrence earlier than traditional imaging. The expanded offerings include Labcorp Plasma Detect ID, a whole exome sequence-guided, personalized panel for patients with stage I–III breast cancer or stage I–IIIA non-small cell lung cancer, and the nationwide availability of Lab
Assessing Labcorp Holdings (LH) Valuation After A Recent 10.5% Three Month Share Price Decline
13.01.2026 07:07
Recent trading in Labcorp Holdings (LH) has drawn attention after the stock showed a 10.5% decline over the past 3 months, prompting investors to reassess its current valuation and long term return profile. See our latest analysis for Labcorp Holdings. The recent 10.5% 3 month share price decline sits against a relatively steady year to date share price return of around flat, while the 1 year total shareholder return of 8.15% suggests momentum has cooled rather than collapsed. If Labcorp’s...
Best Testosterone Replacement Therapy (TRT) 2026: Taurus Meds Consumer Analysis Examines Online TRT Access and At-Home Testosterone Treatment Options
13.01.2026 00:02
Consumer Report Details Low Testosterone Treatment Costs, LabCorp and Quest Lab Testing, Licensed Provider Access, and What Men Need to Know Before Starting Online TRTWILMINGTON, DE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Testosterone replacement therapy requires evaluation by a licensed healthcare provider. If you access services through links in this article, a commission may be earned at no additional cost to yo
Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs
08.01.2026 14:00
SAN JOSE, Calif., January 08, 2026--Today, Visby Medical announced two new relationships that will expand national access to the Visby Women’s Sexual Health Test, the first, at-home, FDA-authorized PCR test for sexually transmitted infections (STIs) available to consumers, enabling immediate access to Visby’s integrated "Test-to-Treat" ecosystem. The palm-sized device delivers confidential results in just 30 minutes, providing women with a rapid response for chlamydia, gonorrhea, and trichomonia
NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp
08.01.2026 13:30
NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE: LH), a leading provider of innovative and comprehensive laboratory services. This strategic move underscores NAMSA's commitment to advancing innovation and accelerating time-to-market for MedTech manufacturers worldwide.
Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks
15.12.2025 15:00
ST. LOUIS, December 15, 2025--Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures. The financing is intended to accelerate Cofactor’s nationwide expansion and broaden patient access to its immunotherapy-response diagnostics.